Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 according to data from Phase III trials conducted on 25,800 participants across India.
The data was submitted to the DCGI over the weekend.
#BharatBiotech #Covaxin #Covid19
An expert panel of India's central drug authority on Thursday recommended granting permission to the Christian Medical College (CMC) in Vellore for conducting a..
Credit: IndiaTimes - Published 1 day ago
After closing the emergency use authorisation (EUA) and Phase-3 clinical trials requests for Bharat Biotech’s Covaxin, Brazil’s health regulator Anvisa..
Credit: IndiaTimes - Published 3 days ago
After suspending the clinical trials of Covaxin following the termination of Bharat Biotech's MoU with its Brazilian partner Precisa Medicamentos, Brazil’s..
Credit: IndiaTimes - Published 4 days ago
Credit: IndiaTimes - Published 1 week ago
In view of a probable third wave of the pandemic, vaccination trials on children have been underway in India with Covaxin and Zydus Cadila's ZyCov-D.
Credit: DNA - Published 1 week ago